No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
carfilzomib
BeiGene Press Release - 3 weeks
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
pomalidomide + daratumumab/hyaluronidase
J&J Press Release - 3 weeks
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
pomalidomide + elotuzumab
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib + panobinostat
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib + pegylated liposomal doxorubicin
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
prednisone + thalidomide + melphalan
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + daratumumab/hyaluronidase
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + elotuzumab
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + daratumumab
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab/hyaluronidase
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
pomalidomide + isatuximab-irfc
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + carfilzomib
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab + pomalidomide
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab + thalidomide
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
thalidomide + daratumumab/hyaluronidase
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
|
Chr t(11;14)
Chr t(11;14)
|
Multiple Myeloma
Multiple Myeloma
|
venetoclax
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + bortezomib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib + elotuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
D-VTd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
ixazomib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
RD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
VMP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
VRD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
bendamustine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
melphalan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
venetoclax + dexamethasone
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
cyclophosphamide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
carfilzomib + panobinostat
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
panobinostat
Sensitive: A2 - Guideline
|
Chr del(17)(p13)
Chr del(17)(p13)
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
carfilzomib + pomalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
PVD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
EloRd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
IRd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
KRd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
DRd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
DVMP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
CyBorD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
EloPd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
Isa-PD
Sensitive: A2 - Guideline
|
Chr t(11;14)
Chr t(11;14)
|
Multiple Myeloma
Multiple Myeloma
|
VenVd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
DVD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
IsaKd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
DKd
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
DCEP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
selinexor + pomalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
selinexor + daratumumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
BVD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
BRD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
ixazomib + pomalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
pomalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + panobinostat
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
galinpepimut-S
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
LCAR-B38M
Sensitive: B - Late Trials
|
Chr amplification(1q)
Chr amplification(1q)
|
Multiple Myeloma
Multiple Myeloma
|
VRD
Resistant: B - Late Trials
|
Chr t(11;14)
Chr t(11;14)
|
Multiple Myeloma
Multiple Myeloma
|
venetoclax + bortezomib
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib + selinexor
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
KD
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
VD
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
DVD
Sensitive: B - Late Trials
|
Chr t(14;16)
Chr t(14;16)
|
Multiple Myeloma
Multiple Myeloma
|
DVD
Sensitive: B - Late Trials
|
|
Multiple Myeloma
Multiple Myeloma
|
DVD
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
lenalidomide + elotuzumab
Sensitive: B - Late Trials
|
CD38 expression
CD38 expression
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
venetoclax + bortezomib + dexamethasone
Sensitive: B - Late Trials
|
Chr del(17p)
Chr del(17p)
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab
Sensitive: B - Late Trials
|
Chr t(14;16)
Chr t(14;16)
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab
Sensitive: B - Late Trials
|
|
Multiple Myeloma
Multiple Myeloma
|
daratumumab
Sensitive: B - Late Trials
|
BCL2 overexpression
BCL2 overexpression
|
Multiple Myeloma
Multiple Myeloma
|
venetoclax
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
PBCAR269A
Sensitive: B - Late Trials
|
TNFRSF17 expression
TNFRSF17 expression
|
Multiple Myeloma
Multiple Myeloma
|
belantamab mafodotin
Sensitive: B - Late Trials
|
RPL5 expression
RPL5 expression
|
Multiple Myeloma
Multiple Myeloma
|
bortezomib
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
selinexor
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Multiple Myeloma
Multiple Myeloma
|
ALLO-715
Sensitive: B - Late Trials
|
Chr t(11;14)
Chr t(11;14)
|
Multiple Myeloma
Multiple Myeloma
|
TD
Resistant: B - Late Trials
|
